Loading
Monoclonal and Polyclonal Antibodies Research / Cancer Research and Treatments · Journal article
Journal of the Egyptian National Cancer Institute · September 4, 2026
Raises a question worth testing. It does not answer one.
This narrative review examines the theoretical and mechanistic basis for using engineered bacteriophages as gene delivery vectors in hepatocellular carcinoma, focusing on phage display, intracellular delivery, TRAIL, and CRISPR/Cas strategies. The authors conclude that while bacteriophages are promising, significant preclinical and translational research is required before clinical utility can be established; current barriers include endosomal escape, immune clearance, and manufacturing scalability.
Narrative review. Hepatocellular carcinoma (HCC); review does not report a studied patient or animal cohort.
Phage display can attach tumor-targeting ligands to phage surface to promote receptor recognition and targeted tumour delivery Therapeutic application is limited by inefficient cytosolic trafficking, endosomal degradation, immune recognition and clearance, vector stability, manufacturing scalability and regulatory issues Engineered bacteriophages are identified as a promising and versatile tool for targeted gene delivery in HCC but require further mechanistic, preclinical and translational research
No quantitative efficacy, safety, or pharmacokinetic data reported; mechanistic and preclinical literature only
This review does not provide evidence-based guidance for clinical practice. It outlines a conceptual framework and research direction; clinicians should not adopt bacteriophage-based approaches for HCC outside of controlled research settings, as no efficacy or safety data are presented.
This is a narrative review synthesizing preclinical and mechanistic concepts about bacteriophage-mediated gene delivery in HCC, raising questions about therapeutic potential rather than reporting empirical trial results or definitive evidence.
As stated by the source record.
This review does not provide evidence-based guidance for clinical practice. It outlines a conceptual framework and research direction; clinicians should not adopt bacteriophage-based approaches for HCC outside of controlled research settings, as no efficacy or safety data are presented.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Liver cancer, mainly hepatocellular carcinoma (HCC), remains a global health burden marked by poor prognosis with limited therapeutic efficacy, and high recurrence rates. HCC remains one of the most lethal malignancies worldwide, with limited therapeutic options and high resistance to conventional treatments. Despite low therapeutic efficacy, molecular heterogeneity, treatment resistance and high recurrence rate, hepatocellular carcinoma (HCC) is still a significant health problem worldwide. These restrictions have stimulated the research of focused methods for delivering therapeutic genetic payload into cancer cells. Bacteriophages have been gaining growing attention as an emerging delivery platform due to their genetic versatility, ease of engineering, ability to be surface modified and payload targeted. In this narrative review, the therapeutic potential of engineered bacteriophages in the context of HCC therapy is critically analyzed focusing on phage display-mediated tumor targeting, phage-mediated intracellular gene delivery, TRAIL gene delivery, and CRISPR/Cas-based therapeutic strategies. It has been previously noted in the literature that phage display can be used to attach tumor-targeting ligands to the surface of a phage, which may aid in the recognition of receptors at the tumor site and promote targeted delivery to the receptor. Therapeutic application is stunted by inefficient trafficking to the cytosol, endosomal degradation, immune recognition and clearance, vector stability, manufacturing scalability and regulatory issues. In conclusion, engineered bacteriophages are a promising and versatile tool for targeted gene delivery in HCC but more mechanistic, preclinical and translational research is needed to prove their therapeutic effectiveness and clinical usefulness for this purpose.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.